Neoadjuvant Nivolumab Shows Benefit in NSCLC Neoadjuvant Nivolumab Shows Benefit in NSCLC
Already used for nonresectable lung cancer, immunotherapy is now heading for the neoadjuvant niche, with nivolumab showing benefit when used before surgery.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer